PHARMACEUTICAL COMPOSITION I CONTEND CONDROITIN SULFATE FUCOSILADO (FucCS) FOR TREATMENT AND PREVENTION OF

NOVELTY – Use of fucosylated chondroitin sulfate compound is claimed for developing drugs for preventing severe forms of malaria and used with complementary therapy. USE – Used in pharmaceutical composition and for developing drugs for preventing severe forms of malaria and used with complementary therapy (claimed), particularly used for treating cerebral and gestational malaria caused by Plasmodium falciparum. ADVANTAGE – The fucosylated chondroitin sulfate compound inhibits endothelial inflammation associated with disease.

Main Application Field

B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)

INVENTORS:

TRINDADE MARANHAO COSTA FABIO
FONTENELLE BASTOS MARCELE
WERNECK CLAUDIO CHRYSOSTOMO
PONTES VICENTE CRISTINA
DE SOUZA MOURAO PAULO ANTONIO
GONCALVES PAVAO MAURO SERGIO
CAROLLO BLANCO YARA

382_INVERTEBRADO

Patent number: BR201001787-A2

PATENT STATUS:

For information contact Inova Unicamp

FOR ADDITIONAL INFORMATION:

parcerias@inova.unicamp.br

+55 (19) 3521-5207 / 2607